Clinical trials: Hyperlipidemias
Hyperlipoproteinemia, Metabolic Syndrome
Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia
The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction…
- Trial name
- NCT01239992
- Testing
- Niacin/ Laropiprant
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Homozygous Familial Hypercholesterolemia
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.
- Trial name
- NCT00730236
- Testing
- AEGR-733
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 29 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Hypertriglyceridemia, Cardiovascular Diseases
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03385239
- Testing
- ISIS 678354
- Where
- 31 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Akcea Therapeutics
Hypercholesterolemia
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.
- Trial name
- SPARQ (NCT01660191)
- Testing
- Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of Kansas Medical Center
Dyslipidemias, Hypercholesterolemia
Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
The current study is proposed to investigate the pattern of dyslipidemia and of lipid treatment practices in patients in India experiencing their first acute cardiovascular event and the extent of residual dyslipidemia after 12…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, High LDL-C
- Trial name
- REMAINS (NCT01245738)
- Volunteers
- 635 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)
To evaluate the percentage of patients with either established cardiovascular disease (CVD), at "high risk" of developing CVD or with diabetes who are on simvastatin 40mg, with fasting LDL-C > 2mmol/l, who are able to attain the…
- Trial name
- NCT00462748
- Testing
- ezetimibe (+) simvastatin, Comparator: atorvastatin, Comparator: rosuvastatin
- Volunteers
- 786 people
- Sponsor
- Organon and Co
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease…
- Trial name
- RADICHOL II (NCT00706849)
- Testing
- mipomersen sodium
- Where
- 48 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Kastle Therapeutics, LLC
HIV Infections, Hyperlipidemia
Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food and Drug Administration (FDA) to treat HIV…
- Trial name
- NCT00630734
- Testing
- Pravastatin, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Dyslipidemias, Hypercholesterolemia
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD
- Trial name
- TANDEM (NCT06005597)
- Testing
- Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe
- Where
- 45 sites in United States
- Volunteers
- 407 people
- Sponsor
- NewAmsterdam Pharma
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with…
- Trial name
- GAUSS-3 (NCT01984424)
- Testing
- Atorvastatin, Ezetimibe
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 511 people
- Sponsor
- Amgen
Coronary Artery Disease, Hypertriglyceridemia
Efficacy of LCQ908 on Cardiovascular Risk
This is a study designed to evaluate the potential for the pradigastat (LCQ908) to impact cardiovascular risk.
- Trial name
- NCT01474434
- Testing
- pradigastat (LCQ908)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Dyslipidemia
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.
- Trial name
- NCT00463606
- Testing
- ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium
- Where
- 168 sites in United States
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Heart Diseases
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia
- Trial name
- HeartPositive (NCT00246376)
- Testing
- Diet, Exercise, Niacin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Baylor College of Medicine
Primary Hypercholesterolemia, Dyslipidemia
Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels
The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.
- Trial name
- NCT00249249
- Testing
- Pitavastatin, Atorvastatin
- Where
- 192 sites in Denmark, Finland and 11 more
- Volunteers
- 830 people
- Sponsor
- Kowa Research Europe
Hypercholesteremia
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography…
- Trial name
- NCT00329160
- Testing
- Rosuvastatin, HMG CoA inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
The primary objective of the study is to assess the pharmacodynamic (PD) effect of alirocumab on serum low density lipoprotein cholesterol (LDL-C) during 14 weeks of subcutaneous (SC) administered alirocumab in patients with…
- Trial name
- NCT01604824
- Testing
- Alirocumab
- Where
- 4 sites in United States, France
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Primary Hypercholesterolemia or Mixed Dyslipidemia
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
The purpose of this study was to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein…
- Trial name
- V-Mono China (NCT05888103)
- Testing
- Inclisiran
- Where
- 28 sites in China
- Volunteers
- 207 people
- Sponsor
- Novartis Pharmaceuticals
Inflammation, Atherosclerosis
Anti-inflammatory Effects of Simvastatin
The purpose of this research study is to determine which of the two ingredients of Vytorin (Simvastatin or Ezetimibe) is responsible for the anti-inflammatory effects of Vytorin
- Conditions
- Inflammation, Atherosclerosis, Hypercholesterolemia
- Trial name
- NCT04638400
- Testing
- Simvastatin 40mg, Ezetimibe 10mg
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- paresh Dandona
Hypercholesterolemia
Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea.
- Trial name
- NCT00166504
- Testing
- ezetimibe (+) simvastatin, atorvastatin
- Volunteers
- 203 people
- Sponsor
- Organon and Co